Physician profile
John H Dewitt
NPI 1952497653
$220,516.94
in general payments reported to CMS, 2019-2025
14 companies · $95.04 in 2025
The $95.04 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $23K · 2021: $41K · 2022: $42K · 2023: $61K · 2024: $26K · 2025: $95.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $77K · Travel and Lodging: $7,765 · Food and Beverage: $1,872 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $76,980.00 |
| Travel and Lodging | $7,765.48 |
| Food and Beverage | $1,872.39 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $149,572.48 | 2021-2025 | Vraylar |
| Allergan, INC. | $53,998.36 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $11,254.99 | 2023-2024 | Uzedy, Austedo Xr |
| Vanda Pharmaceuticals INC. | $5,313.78 | 2024 | Fanapt |
| Janssen Pharmaceuticals, INC | $123.30 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.89 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.28 | 2022-2023 | Trintellix |
| Lundbeck LLC | $27.14 | 2025 | Vyepti |
| Otsuka America Pharmaceutical, INC. | $26.75 | 2025 | Rexulti |
| Corium, LLC | $23.20 | 2023 | Azstarys |
| Neurocrine Biosciences, INC. | $19.06 | 2022 | |
| Axsome Therapeutics, INC. | $18.89 | 2022 | |
| Alkermes, INC. | $18.12 | 2025 | Aristada, Lybalvi |
| Bausch Health US, LLC | $14.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dewitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.